Quadruplet regimen for newly diagnosed multiple myeloma is effective in the standard-risk subgroup but not in the high-risk subgroup.

MLA

Jianghua Ding, and Shengping Gong. “Quadruplet Regimen for Newly Diagnosed Multiple Myeloma Is Effective in the Standard-Risk Subgroup but Not in the High-Risk Subgroup.” Frontiers in Pharmacology, May 2024, pp. 1–4. EBSCOhost, https://doi.org/10.3389/fphar.2024.1398879.

APA

Jianghua Ding, & Shengping Gong. (2024). Quadruplet regimen for newly diagnosed multiple myeloma is effective in the standard-risk subgroup but not in the high-risk subgroup. Frontiers in Pharmacology, 1–4. https://doi.org/10.3389/fphar.2024.1398879

Chicago

Jianghua Ding, and Shengping Gong. 2024. “Quadruplet Regimen for Newly Diagnosed Multiple Myeloma Is Effective in the Standard-Risk Subgroup but Not in the High-Risk Subgroup.” Frontiers in Pharmacology, May, 1–4. doi:10.3389/fphar.2024.1398879.